iNtRON Biotechnology Inc., established in 1999 and headquartered in Seongnam-si, South Korea, is a biotechnology company specializing in the development of novel drugs targeting bacterial infectious diseases. The company's research focuses on bacteriophage-derived endolysins and other innovative therapeutic approaches.
Key Areas of Focus:
- Endolysin-Based Therapeutics: iNtRON is developing treatments utilizing endolysins—enzymes derived from bacteriophages—that can effectively lyse bacterial cells, offering potential solutions against antibiotic-resistant bacteria.
- Bacteriophage Applications: Beyond endolysins, the company explores the use of bacteriophages in modulating the gut microbiome to eliminate harmful bacteria, thereby promoting a healthy microbiota and addressing diseases associated with microbial imbalances.
- ntiviral Technologies: iNtRON is also developing antiviral strategies, such as the PHAGERUS® platform, aimed at neutralizing viruses and contributing to vaccine development and antiviral therapies.
